



Published in final edited form as:

*Pediatr Res.* 2009 April ; 65(4): . doi:10.1203/PDR.0b013e3181994b85.

## URINARY PROSTASIN: A POSSIBLE BIOMARKER FOR RENAL PRESSURE NATRIURESIS IN BLACK ADOLESCENTS

Haidong Zhu<sup>1</sup>, Julie Chao<sup>2</sup>, Dehuang Guo<sup>1</sup>, Ke Li<sup>1</sup>, Ying Huang<sup>1</sup>, Kimberly Hawkins<sup>1</sup>, Nikki Wright<sup>1</sup>, Inger Stallmann-Jorgenson<sup>1</sup>, Weili Yan<sup>1</sup>, Gregory A. Harshfield<sup>1</sup>, and Yanbin Dong<sup>1</sup>

<sup>1</sup>Georgia Prevention Institute, Department of Pediatrics, Medical College of Georgia, Augusta, Georgia, USA 30907

<sup>2</sup>Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina, USA 29425

### Abstract

Prostasin is a membrane-bound/secretive serine protease interacting with aldosterone and the epithelial sodium channel in the kidney. We and others have previously proposed the concept of stress-induced pressure natriuresis (SIPN) where increased urinary sodium excretion ( $U_{NaV}$ ) is coupled with elevated blood pressure (BP) in response to behavioral stress in normotensive adolescents. This study thus aimed to test the relationship between prostasin and pressure natriuresis using the SIPN model. A cohort of 102 normotensive black adolescents (mean age:  $17.0 \pm 1.2$  years; 56% females) were placed on a controlled sodium ( $4000 \pm 200$  mg/day) and potassium ( $2600 \pm 200$  mg/day) diet for three days before testing. The SIPN protocol consisted of a one-hour baseline period, a one-hour stress period (competitive video games), and a one-hour recovery period. During the stress period, BP elevation was coupled with an increase in  $U_{NaV}$ . Urinary prostasin concentration had more than a two-fold reduction from baseline ( $38.4 \pm 32.7$  ng/ml) to stress ( $17.2 \pm 16.0$  ng/ml), and further declined during recovery ( $12.1 \pm 16.2$  ng/ml) ( $p < 0.001$ ). Urinary prostasin was inversely correlated with  $U_{NaV}$  during stress ( $r = -0.43$ ,  $p = 0.0001$ ), even after being normalized by urinary creatinine. Our data suggest that urinary prostasin could be a novel biomarker and/or mechanism for renal pressure natriuresis in normotensive black adolescents.

### Keywords

prostasin; adolescents; pressure natriuresis; blood pressure; urinary sodium excretion

### INTRODUCTION

Renal pressure natriuresis, one of the key mechanisms of blood pressure (BP) homeostasis (1), is critically dependent upon the activity of sodium channels and transporters expressed in the nephron. Chief among these are the epithelial sodium channels (ENaC) consisting of three subunits, ENaC, ENaC and ENaC in the cortical collecting duct (2, 3). Although sodium reabsorption by ENaC accounts for only a relatively small proportion (less than 5%), it constitutes the rate-limiting step and the final renal adjustment to sodium balance (4).

Multiple mechanisms such as hormones, intracellular factors, and accessory regulatory proteins regulate ENaC function (2, 3). Aldosterone stimulates ENaC expression and activates an ENaC-regulating protein kinase, serum and glucocorticoid-regulated kinase 1 (SGK1). SGK1 inhibits ENaC ubiquitination by an ubiquitin ligase, the neural precursor cell expressed developmentally down-regulated 4-like protein (Nedd4L), and subsequently prevents channel degradation. A series of studies previously indicated that numerous proteases such as prostaticin, a glycosylphosphatidylinositol (GPI)-anchored serine protease expressed in the distal nephron, are involved in the proteolytic processing and activation of ENaC subunits in *Xenopus* oocytes and a mouse cortical collecting duct cell line (5–16). Prostaticin was thought to induce cleavage of an inhibitory peptide from ENaC to activate the channel fully in the cell (16–18). Of interest, aldosterone enhanced the expression of prostaticin mRNA and protein in the cultured mouse cortical collecting duct cell line and in rats (19). In contrast, a single injection of adenovirus carrying the human prostaticin gene caused a prolonged (3 to 4 weeks) increase in BP and plasma aldosterone concentration in rats, indicating that prostaticin may cause BP elevation via the stimulation of aldosterone (20). Furthermore, a decrease in urinary prostaticin excretion by a synthetic prostaticin inhibitor resulted in an increase in urinary sodium excretion in Sprague-Dawley rats (21). These findings suggest that prostaticin may participate in tubular sodium reabsorption and pressure natriuresis via either direct effects on ENaC or interactions with aldosterone.

Comparable data in humans are scarce. Therefore, the purpose of this study was to examine the relationship among prostaticin and renal pressure natriuresis in normotensive adolescents by using our stress-induced pressure natriuresis (SIPN) model (22–27). This model examines changes in pressure natriuresis induced by mental stress, which consists of a one-hour baseline period, a one-hour stress period (competitive video games), and a one-hour recovery period. The SIPN hypothesis postulates that a stress-induced increase in BP leads to a corresponding increase in urinary sodium excretion ( $U_{NaV}$ ). Impaired stress-induced sodium regulation and resultant extracellular volume expansion may lead to the future development of hypertension and its sequelae. The second goal of this study was to examine the interaction between aldosterone and prostaticin during SIPN. We examined healthy normotensive black adolescents because 1) healthy normotensive adolescents may not have yet developed significant target organ damage, which can mask or compromise the normal response pattern; 2) the pressure natriuresis concept is particularly appealing owing to the greater sensitivity of BP to sodium in blacks compared to their white counterparts (28, 29); and 3) urinary prostaticin could be used as a possible biomarker to screen adolescents at risk of BP elevation.

## METHODS

### Subject recruitment

The protocol was approved by the Human Assurance Committee of the Medical College of Georgia. A sample of 102 healthy normotensive black adolescents including 45 males and 57 females were recruited from local public high schools in the Augusta-Richmond County area via school announcements, flyers, handout, or word of mouth. Written informed parental consent and subject assent were obtained before testing. Black race (African American) was identified by self-report of each subject, and by parent if the subject was under 18 years of age. Normotension was based on BP screening, namely, <95<sup>th</sup> percentile for age, sex and height, or <140/90 mmHg for subjects aged 18 years or older (30). Other exclusion criteria included any chronic illness, medication use, or a positive pregnancy test.

## Protocol

Weight, height, and BP were obtained at a screening visit before initiating the study protocol. The SIPN protocol has been previously described in detail (25–27). Briefly, subjects were placed on a controlled sodium and potassium diet for 3 days before testing. To do this, we met with the subjects before the week of their scheduled testing and planned each meal for each day, based on an average sodium and potassium intake of  $4000 \pm 200$  mg/day and  $2600 \pm 200$  mg/day, respectively. Girls were not tested while on their menses, and were tested on the week following the completion of menstrual flow to ensure all girls were tested in the same phase of their menstrual cycle. During the test week the meals were packed into coolers each day and the subjects or parents picked up the coolers from the Georgia Prevention Institute. Overnight urine collection was used to estimate the subject's compliance with the sodium-controlled diet. On the fourth day the subjects performed the stress test, after having a breakfast provided. They were seated in a comfortable chair for the entire protocol, and ambulation was only allowed for collection of urine samples. The subjects emptied their bladders at the beginning of the baseline period. The protocol included a baseline period of one-hour (hour 1) during which the subjects watched a movie. This was followed by a one-hour stress period (hour 2) during which a competitive video game task (Snowboard, Sony Corp., Foster City, CA) was played for a monetary reward between two subjects. Finally, there was a one-hour post-stress recovery period (hour 3) that was the same as the baseline period. Urine samples were obtained hourly, and hour 1 was considered as baseline  $U_{NaV}$  to insure that the subjects had similar urinary flow rates. Hour 2 and hour 3 were considered stress  $U_{NaV}$  and recovery  $U_{NaV}$ , respectively. BP was measured by a Dinamap monitor (Dinamap Compact Monitor, Tampa, FL) at an interval of 15 minutes. The individual BP values during each hour were averaged to obtain baseline BP (hour 1), stress BP (hour 2), and recovery BP (hour 3). The subjects were required to drink 250 ml of water every hour to insure that they remained hydrated and provided adequate urine samples.

## Human urinary prostatic measurement

Urinary levels of immunoreactive human prostatic were determined by enzyme-linked immunosorbent assay (ELISA) prepared with the previously described antibody to human prostatic (31). Microtiter plates (96-well) were coated with anti-prostatic immunoglobulin G (IgG) (1  $\mu$ g/mL, 100  $\mu$ L per well) overnight at 4 °C. Purified prostatic standards 0.16–10 ng) or samples were added to individual wells in a total volume of 100  $\mu$ L of phosphate-buffered saline containing 0.05% Tween 20 and 0.5% gelatin (dilution buffer and incubated at 37 °C for 90 minutes. Biotin-labeled anti-human prostatic IgG was added in each well at a concentration of 1  $\mu$ g/mL in a total of 100  $\mu$ L and incubated at 37 °C for 60 minutes. Peroxidase-avidin at a concentration of 1  $\mu$ g/mL in a total volume of 100  $\mu$ L was added and incubated at 37 °C for 30 minutes. The color reaction was performed by adding 100  $\mu$ L of freshly prepared substrate solution [0.03% 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) and 0.03%  $H_2O_2$  in 0.1 M sodium citrate (pH 4.3)] to each well and incubating the mixture at room temperature for 30 minutes. The plates were read at 405 nm with a plate reader (Titertek Instruments Inc., Huntsville, AL).

## Aldosterone, electrolyte and creatinine measurements

Aldosterone levels were determined using a competitive enzyme RIA kit (Diagnostic Systems Laboratories, Webster, TX). The sensitivity of the assay was 12 pg/ml. Intra-assay coefficient of variation was 7.1%; and inter-assay coefficient of variation was 13.2%.

Electrolytes and creatinine were analyzed by the ion selective electrode technique using a NOVA 16 Analyzer (NOVA Biomedical, Waltham, MA). The NOVA has an intra-assay coefficient of variation of less than 3% and an inter-assay coefficient of 4%.

## Statistical analyses

The general characteristics of subjects were presented as mean  $\pm$  SD. The variations of clinical phenotypes among baseline (hour 1), stress (hour 2) and recovery (hour 3) were analyzed by repeated measures ANOVA, with adjustment of age, sex and body mass index (BMI). The correlations between urinary prostaticin concentration and urinary prostaticin concentration normalized by urinary creatinine, and  $U_{Na}V$  or plasma aldosterone were tested by simple bivariate correlation analyses, or partial correlation analyses to adjust for potential confounders such as age, sex and BMI. Log-transformation was performed to obtain approximation of normal distribution when necessary. A value of  $p < 0.05$  was deemed statistically significant. The statistical analyses were performed with STATA 8.0 (StataCorp, College Station, TX).

## RESULTS

The subject characteristics are presented in Table 1. Subjects were normotensive black adolescents aged  $17.0 \pm 1.2$  years. The average height of the subjects was  $170.2 \pm 8.7$  cm, and the average BMI was  $25.3 \pm 5.4$  kg/m<sup>2</sup>. The values of plasma creatinine and plasma aldosterone were within normal ranges. Urinary prostaticin was detectable in every subject, regardless of sex.

As shown in Table 1, the increment of systolic BP (SBP) and diastolic BP (DBP) from baseline (hour 1) to stress (hour 2) was approximately 4 to 5 mmHg, and both SBP and DBP dropped significantly during recovery (hour 3) as compared to stress ( $P < 0.001$ ). Similarly,  $U_{Na}V$  was increased almost two-fold from baseline ( $7.0 \pm 4.1$  mEq/hr) to stress ( $12.9 \pm 8.5$  mEq/hr) ( $p < 0.001$ ), and declined during recovery ( $9.9 \pm 6.8$  mEq/hr) as compared to stress ( $p = 0.04$ ). Conversely, urinary prostaticin concentration had more than a two-fold reduction from baseline ( $38.4 \pm 32.7$  ng/ml) to stress ( $17.2 \pm 16.0$  ng/ml), and continuously declined during recovery ( $12.1 \pm 16.2$  ng/ml) as compared to stress ( $p < 0.001$ ). As shown in Figure 1, urinary prostaticin was inversely correlated with  $U_{Na}V$  during stress ( $r = -0.43$ ,  $p = 0.0001$ ), even after being normalized by urinary creatinine. Urinary prostaticin did not correlate with  $U_{Na}V$  at baseline ( $r = 0.06$ ,  $p = 0.60$ ) or  $U_{Na}V$  during recovery ( $r = 0.07$ ,  $p = 0.3$ ).

Plasma levels of aldosterone were significantly reduced during stress ( $99.9 \pm 57.1$  pg/ml) compared to baseline ( $115.1 \pm 61.0$  pg/ml) and remained lower during recovery ( $101.5 \pm 55.2$  pg/ml) ( $p < 0.001$ ). We did not find any significant correlations between aldosterone, and  $U_{Na}V$  or prostaticin at baseline, stress or recovery.

## DISCUSSION

For sodium balance to be maintained in the face of increased arterial pressure, there must be a shift of renal pressure natriuresis to higher BP (1, 32). The laboratory-based pressure natriuresis model (SIPN) exhibited a higher rate of  $U_{Na}V$  when BP was elevated, which is a normal natriuretic response in healthy normotensive adolescents. We undertook the present study to test for the relationship between urinary prostaticin and the natriuretic process in response to stress-induced BP elevation, after controlling dietary sodium and potassium intake. Our data demonstrated that there was a decrease in urinary prostaticin concentration from baseline to stress, and from stress to recovery. In particular, from baseline to stress, urinary prostaticin concentration decreased two-fold, while  $U_{Na}V$  increased almost two-fold. Furthermore, prostaticin was inversely correlated with  $U_{Na}V$  during stress, that is, lower prostaticin was associated with higher  $U_{Na}V$ . These findings suggest that prostaticin could be involved in renal sodium reabsorption, and thus the renal-body fluid control of arterial pressure.

Discovered more than a decade ago, prostaticin is one of the only two known mammalian serine proteases that are attached to the plasma membrane via a GPI anchor (10, 33, 34). It has been predominantly studied in the pathological development of tumors and cancer such as prostate, breast, and ovarian cancer (10, 31, 35). Prostaticin has recently attracted substantial attention as a potential mechanism underlying sodium and volume homeostasis and subsequent BP regulation, although the production, secretion and clearance of distal tubular prostaticin and urinary prostaticin are largely unknown. It is believed that prostaticin has channel activating properties via the proteolytic cleavage of ENaC (16–18). Indeed, at the post-translational level, proteolytic processing is thought to be important if not essential to ENaC activation.

On the other hand, aldosterone regulates sodium balance, extracellular fluid volume, and BP (2, 36, 37). Aldosterone increases the rate of tubular sodium reabsorption across epithelia at the distal nephron by enhancing ENaC activity. Previously, Narikiyo *et al* showed that urinary prostaticin secretion was substantially increased in three patients with primary aldosteronism, and that adrenalectomy significantly reduced urinary prostaticin secretion (19). In an independent study, Olivieri *et al* demonstrated that spironolactone (100 mg), the traditional aldosterone receptor inhibitor, decreased urinary prostaticin in five normotensive white adults in whom the renin/aldosterone axis was activated by low sodium intake (defined by urinary sodium <150 mmol/day in 24-hour urine), but it was ineffective in five subjects with high sodium intake (defined by urinary sodium >150 mmol/day in 24-hour urine) (38). Of note, urinary prostaticin was evaluated by SDS-PAGE 2D gels, and Western blotting, which are generally considered to be less accurate and robust at the population level as compared to the ELISA technique used in this present study. We placed our subjects on a sodium- and potassium- controlled diet, yet failed to identify a significant correlation between aldosterone and prostaticin at baseline, during stress, or recovery. Wang *et al* evaluated the effects of adenovirus-mediated gene transfer of human prostaticin on BP regulation and sodium reabsorption in Wistar rats. Elevated plasma aldosterone levels were detected 3 days after gene transfer before the development of hypertension, indicating that stimulation of mineralocorticoid production was a primary target of prostaticin (20). Alternatively, prostaticin might modulate the pressure natriuresis relation, independent of aldosterone.

This study has some limitations. First, plasma and urine samples were collected and assayed only hourly throughout the SIPN protocol. Sample collections at more time points may enable us to reveal the dynamic relationship between prostaticin and  $U_{NaV}$  better. Second, the basal levels of urinary prostaticin in our subjects were not examined because we did not collect urine samples prior to the start of the sodium-controlled diet. Decreased dietary sodium intake might exaggerate the role of prostaticin via the activation of aldosterone. On the other hand, in our SIPN model, aldosterone was suppressed in response to stress, which might mask the true relationship between aldosterone and prostaticin under stress. The dynamic relationship among urinary prostaticin, salt intake, and aldosterone in normotensive adolescents needs to be studied using a salt sensitivity test, e.g., low salt diet (50 mmol/day) for five days followed by high salt (150 mmol/day) supplementation for ten days (39, 40). Third, as discussed above, since plasma aldosterone was only measured hourly, we cannot exclude the role of aldosterone in the pressure natriuresis relation over time in the SIPN model, even though no significant correlations between aldosterone and  $U_{NaV}$  were found across baseline, stress and recovery.

Nonetheless, there have been only few studies investigating the role of prostaticin in sodium balance in humans, although prostaticin expressed in the distal nephron has been suggested to be an ENaC regulatory mechanism *in vitro* and in animals since the late 1990s. Our data are the first to indicate that prostaticin is likely involved in pressure natriuresis at the population

level, specifically in black adolescents. Clinically, considering that urine is easily collected and represents a medium with a relatively low number of interfering proteins, urinary prostaticin may be used as a possible biomarker for renal pressure and natriuresis. Our data in black adolescents warrant replication in other populations including white adolescents, normotensive adults, and patients with essential hypertension. Finally, although the cross-sectional correlation between prostaticin and stress-induced  $U_{NaV}$  was recognized, a longitudinal study with repeated measures over time is under way to elucidate the contribution of prostaticin to pressure natriuresis and BP further in youth.

## Acknowledgments

This study was supported by a grant from National Heart, Lung, and Blood Institute (HL077230).

## ABBREVIATIONS

<b>BP</b>	blood pressure
<b>ENaC</b>	epithelial sodium channel
<b>SIPN</b>	stress induced pressure natriuresis
<b><math>U_{NaV}</math></b>	urinary sodium excretion

## REFERENCE


1. Guyton AC, Coleman TG. Quantitative analysis of the pathophysiology of hypertension. *Circ Res.* 1969; 24:1–19. [PubMed: 4306217]
2. Garty H, Palmer LG. Epithelial sodium channels: function, structure, and regulation. *Physiol Rev.* 1997; 77:359–396. [PubMed: 9114818]
3. Gormley K, Dong Y, Sagnella GA. Regulation of the epithelial sodium channel by accessory proteins. *Biochem J.* 2003; 371:1–14. [PubMed: 12460120]
4. Pratt JH. Central role for ENaC in development of hypertension. *J Am Soc Nephrol.* 2005; 16:3154–3159. [PubMed: 16192416]
5. Vallet V, Chraïbi A, Gaeggeler HP, Horisberger JD, Rossier BC. An epithelial serine protease activates the amiloride-sensitive sodium channel. *Nature.* 1997; 389:607–610. [PubMed: 9335501]
6. Vallet V, Horisberger JD, Rossier BC. Epithelial sodium channel regulatory proteins identified by functional expression cloning. *Kidney Int Suppl.* 1998; 67:S109–S114. [PubMed: 9736264]
7. Chraïbi A, Vallet V, Firsov D, Hess SK, Horisberger JD. Protease modulation of the activity of the epithelial sodium channel expressed in *Xenopus* oocytes. *J Gen Physiol.* 1998; 111:127–138. [PubMed: 9417140]
8. Vuagniaux G, Vallet V, Jaeger NF, Pfister C, Bens M, Farman N, Courtois-Coutry N, Vandewalle A, Rossier BC, Hummler E. Activation of the amiloride-sensitive epithelial sodium channel by the serine protease mCAP1 expressed in a mouse cortical collecting duct cell line. *J Am Soc Nephrol.* 2000; 11:828–834. [PubMed: 10770960]
9. Adachi M, Kitamura K, Miyoshi T, Narikiyo T, Iwashita K, Shiraishi N, Nonoguchi H, Tomita K. Activation of epithelial sodium channels by prostaticin in *Xenopus* oocytes. *J Am Soc Nephrol.* 2001; 12:1114–1121. [PubMed: 11373334]
10. Chen LM, Skinner ML, Kauffman SW, Chao J, Chao L, Thaler CD, Chai KX. Prostaticin is a glycosylphosphatidylinositol-anchored active serine protease. *J Biol Chem.* 2001; 276:21434–21442. [PubMed: 11274175]
11. Vallet V, Pfister C, Loffing J, Rossier BC. Cell-surface expression of the channel activating protease xCAP-1 is required for activation of ENaC in the *Xenopus* oocyte. *J Am Soc Nephrol.* 2002; 13:588–594. [PubMed: 11856761]
12. Vuagniaux G, Vallet V, Jaeger NF, Hummler E, Rossier BC. Synergistic activation of ENaC by three membrane-bound channel-activating serine proteases (mCAP1, mCAP2, and mCAP3) and



- serum- and glucocorticoid-regulated kinase (Sgk1) in *Xenopus* Oocytes. *J Gen Physiol.* 2002; 120:191–201. [PubMed: 12149280]
13. Hughey RP, Mueller GM, Bruns JB, Kinlough CL, Poland PA, Harkleroad KL, Carattino MD, Kleyman TR. Maturation of the epithelial Na<sup>+</sup> channel involves proteolytic processing of the alpha- and gamma-subunits. *J Biol Chem.* 2003; 278:37073–37082. [PubMed: 12871941]
  14. Rossier BC. The epithelial sodium channel: activation by membrane-bound serine proteases. *Proc Am Thorac Soc.* 2004; 1:4–9. [PubMed: 16113404]
  15. Kleyman TR, Myerburg MM, Hughey RP. Regulation of ENaCs by proteases: An increasingly complex story. *Kidney Int.* 2006; 70:1391–1392. [PubMed: 17024162]
  16. Hughey RP, Carattino MD, Kleyman TR. Role of proteolysis in the activation of epithelial sodium channels. *Curr Opin Nephrol Hypertens.* 2007; 16:444–450. [PubMed: 17693760]
  17. Carattino MD, Sheng S, Bruns JB, Pilewski JM, Hughey RP, Kleyman TR. The epithelial Na<sup>+</sup> channel is inhibited by a peptide derived from proteolytic processing of its alpha subunit. *J Biol Chem.* 2006; 281:18901–18907. [PubMed: 16690613]
  18. Bruns JB, Carattino MD, Sheng S, Maarouf AB, Weisz OA, Pilewski JM, Hughey RP, Kleyman TR. Epithelial Na<sup>+</sup> channels are fully activated by furin- and prostaticin-dependent release of an inhibitory peptide from the gamma-subunit. *J Biol Chem.* 2007; 282:6153–6160. [PubMed: 17199078]
  19. Narikiyo T, Kitamura K, Adachi M, Miyoshi T, Iwashita K, Shiraishi N, Nonoguchi H, Chen LM, Chai KX, Chao J, Tomita K. Regulation of prostaticin by aldosterone in the kidney. *J Clin Invest.* 2002; 109:401–408. [PubMed: 11828000]
  20. Wang C, Chao J, Chao L. Adenovirus-mediated human prostaticin gene delivery is linked to increased aldosterone production and hypertension in rats. *Am J Physiol Regul Integr Comp Physiol.* 2003; 284:R1031–R1036. [PubMed: 12626364]
  21. Iwashita K, Kitamura K, Narikiyo T, Adachi M, Shiraishi N, Miyoshi T, Nagano J, Tuyen DG, Nonoguchi H, Tomita K. Inhibition of prostaticin secretion by serine protease inhibitors in the kidney. *J Am Soc Nephrol.* 2003; 14:11–16. [PubMed: 12506133]
  22. Harshfield GA, Treiber FA, Davis H, Kapuku GK. Impaired stress-induced pressure natriuresis is related to left ventricle structure in blacks. *Hypertension.* 2002; 39:844–847. [PubMed: 11967237]
  23. Harshfield GA, Wilson ME, Hanevold C, Kapuku GK, Mackey L, Gillis D, Treiber FA. Impaired stress-induced pressure natriuresis increases cardiovascularload in African American youths. *Am J Hypertens.* 2002; 15:903–906. [PubMed: 12372678]
  24. Barbeau P, Litaker MS, Harshfield GA. Impaired pressure natriuresis in obese youths. *Obes Res.* 2003; 11:745–751. [PubMed: 12805395]
  25. Wilson ME, Harshfield GA, Ortiz L, Hanevold C, Kapuka G, Mackey L, Gillis D, Edmonds L, Evans C. Relationship of body composition to stress-induced pressure natriuresis in youth. *Am J Hypertens.* 2004; 17:1023–1028. [PubMed: 15533728]
  26. Harshfield GA, Wilson ME, McLeod K, Hanevold C, Kapuku GK, Mackey L, Gillis D, Edmonds L. Adiposity is related to gender differences in impaired stress-induced pressure natriuresis. *Hypertension.* 2003; 42:1082–1086. [PubMed: 14581294]
  27. Hanevold CD, Pollock JS, Harshfield GA. Racial Differences in Microalbumin Excretion in Healthy Adolescents. *Hypertension.* 2008; 51:334–338. [PubMed: 18172060]
  28. Weinberger MH. Racial differences in renal sodium excretion: relationship to hypertension. *Am J Kidney Dis.* 1993; 21:41–45. [PubMed: 8465835]
  29. Falkner B. Differences in blacks and whites with essential hypertension: biochemistry and endocrine. State of the art lecture. *Hypertension.* 1990; 15:681–686. [PubMed: 2190920]
  30. Zhu H, Yan W, Ge D, Treiber FA, Harshfield GA, Kapuku G, Snieder H, Dong Y. Relationships of cardiovascular phenotypes with healthy weight, at risk of overweight, and overweight in US youths. *Pediatrics.* 2008; 121:115–122. [PubMed: 18166564]
  31. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW. Prostaticin, a potential serum marker for ovarian cancer: identification through microarray technology. *J Natl Cancer Inst.* 2001; 93:1458–1464. [PubMed: 11584061]
  32. Hall JE. The kidney, hypertension, and obesity. *Hypertension.* 2003; 41:625–633. [PubMed: 12623970]

33. Yu JX, Chao L, Chao J. Prostaticin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. *J Biol Chem.* 1994; 269:18843–18848. [PubMed: 8034638]
34. Yu JX, Chao L, Chao J. Molecular cloning, tissue-specific expression, and cellular localization of human prostaticin mRNA. *J Biol Chem.* 1995; 270:13483–13489. [PubMed: 7768952]
35. Chen LM, Chai KX. Prostaticin serine protease inhibits breast cancer invasiveness and is transcriptionally regulated by promoter DNA methylation. *Int J Cancer.* 2002; 97:323–329. [PubMed: 11774283]
36. Funder JW. Aldosterone action. *Annu Rev Physiol.* 1993; 55:115–130. [PubMed: 8466169]
37. Connell JM, Davies E. The new biology of aldosterone. *J Endocrinol.* 2005; 186:1–20. [PubMed: 16002531]
38. Olivieri O, Castagna A, Guarini P, Chiecchi L, Sabaini G, Pizzolo F, Corrocher R, Righetti PG. Urinary prostaticin: a candidate marker of epithelial sodium channel activation in humans. *Hypertension.* 2005; 46:683–688. [PubMed: 16172430]
39. Wilson DK, Sica DA, Miller SB. Effects of potassium on blood pressure in salt-sensitive and salt-resistant black adolescents. *Hypertension.* 1999; 34:181–186. [PubMed: 10454438]
40. Wilson DK, Bayer L, Sica DA. Variability in salt sensitivity classifications in black male versus female adolescents. *Hypertension.* 1996; 28:250–255. [PubMed: 8707390]





**Figure 1.** Correlations between urinary prostasin normalized by creatinine and  $U_{NaV}$  during stress. There were significant and negative correlations between urinary prostasin excretion (urinary prostasin concentration normalized by urinary creatinine concentration) and  $U_{NaV}$  during stress ( $r=-0.43$ ,  $p=0.0001$ ) (adjusted for age, sex and body mass index).

Table 1

## General Clinical Characteristics

	Baseline	Stress	Recovery	P <sub>overall</sub>	P <sub>b-s</sub>	P <sub>s-r</sub>
Age, years (n=102)	17.0±1.2	—	—	—	—	—
Male/female	45/57	—	—	—	—	—
Height, cm	170.2±8.7	—	—	—	—	—
Body mass index, kg/m <sup>2</sup>	25.3±5.4	—	—	—	—	—
Systolic BP, mm Hg	110 ± 12	115 ± 12	109 ± 11	<0.001	<0.001	<0.001
Diastolic BP, mm Hg	60 ± 6	64 ± 6	60 ± 6	<0.001	<0.001	<0.001
Plasma sodium, mmol/L*	136.7 ± 5.6	135.8 ± 6.0	136.2 ± 5.1	0.441	0.205	0.631
Plasma potassium, mmol/L*	4.4 ± 0.3	4.3 ± 0.4	4.3 ± 0.3	0.911	0.888	0.775
Plasma creatinine, mg/dL*	1.0 ± 0.4	0.9 ± 0.4	0.9 ± 0.4	0.038	0.046	0.685
Plasma aldosterone, pg/ml*	115.1 ± 61.0	99.9 ± 57.1	101.5 ± 55.2	<0.001	<0.001	0.521
Urinary creatinine, mg/dL*	114.8 ± 95.0	65.0±49.4	53.4 ± 46.5	<0.001	<0.001	<0.001
Urinary prostaticin concentration, ng/ml	38.4 ± 32.7	17.2 ± 16.0	12.1 ± 16.2	<0.001	<0.001	<0.001
Urinary prostaticin excretion, ng/mg**	28 ± 11	26 ± 11	23 ± 10	0.005	0.038	0.014
U <sub>Na</sub> V, mEq/hr*	7.0 ± 4.1	12.9 ± 8.5	9.9 ± 6.8	<0.001	<0.001	0.041

Values = means ± SD. The repeated ANOVA analyses were applied to analyze the overall and subgroup differences in variables across baseline (hour 1), stress (hour 2) and recovery (hour 3), with adjustment of age, sex and body mass index. P<sub>b-s</sub>: baseline to stress; P<sub>s-r</sub>: stress to recovery.

\* Analyses were performed based on log transformed data;

\*\* Urinary prostaticin excretion was calculated as urinary prostaticin concentration divided by urinary creatinine concentration.